A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

BACKGROUND: Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6–17 years) with moderate‐to‐severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk–benefit profile in younger children remains a significant unmet need. OBJECTIVES: To det...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Eur Acad Dermatol Venereol
Asıl Yazarlar: Paller, A.S., Siegfried, E.C., Simpson, E.L., Cork, M.J., Lockshin, B., Kosloski, M.P., Kamal, M.A., Davis, J.D., Sun, X., Pirozzi, G., Graham, N.M.H., Gadkari, A., Eckert, L., Ruddy, M., Bansal, A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Allergy and Eczema
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894166/
https://ncbi.nlm.nih.gov/pubmed/32893393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16928
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller